Skip to main
GMAB

GMAB Stock Forecast & Price Target

GMAB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Genmab is seeing positive results from its EPCORE DLBCL trials for EPKINLY, with statistically significant and clinically meaningful improvement in PFS. This, combined with the drug's accelerated approval and strong data in phase 2 trials, leads to a high probability of approval in 1L and 2L+ DLBCL settings. With these developments in mind, and after accounting for potential costs related to acquisitions and integration, the outlook for Genmab's stock is positive with a Buy rating and a price target of $40, up from the previous $38.

Bears say

Genmab is likely to experience a decline in profits due to the high levels of acquisition and integration charges compared to previous quarters. The company's heavy reliance on partner products like Darzalex and Tepezza also raises concerns about potential fluctuations in revenue and profitability in the future. Additionally, the competition in the biotechnology industry and the uncertainty surrounding FDA approvals could add further risk to Genmab's stock.

GMAB has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Genmab - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Genmab - ADR (GMAB) Forecast

Analysts have given GMAB a Buy based on their latest research and market trends.

According to 7 analysts, GMAB has a Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Genmab - ADR (GMAB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.